A Study of NCS-01 in Patients With Acute Ischemic Stroke
Status:
Not yet recruiting
Trial end date:
2021-10-01
Target enrollment:
Participant gender:
Summary
This is an initial Phase1/2 dose-finding, double-blind, placebo-controlled, multi-center
study to evaluate the safety and tolerability of NCS-01 in patients with acute ischemic
stroke. All patients will be randomized within 24 hours of stroke onset. This study will be
conducted in 2 stages.